-+ 0.00%
-+ 0.00%
-+ 0.00%

Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price Target

Benzinga·07/20/2026 18:15:04
Listen to the news
Maxim Group analyst Jason McCarthy upgrades Akari Therapeutics (NASDAQ:AKTX) from Hold to Buy and announces $30 price target.